Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Lapatinib + 1,23 mg Eribulin|DRUG: Lapatinib + 1,76 mg Eribulin
Sponsor: German Breast Group